Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 1.00
NAS:CRME's Cash-to-Debt is ranked lower than
81% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. NAS:CRME: 1.00 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:CRME' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.64  Med: 57.47 Max: No Debt
Current: 1
Equity-to-Asset 0.42
NAS:CRME's Equity-to-Asset is ranked lower than
72% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NAS:CRME: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:CRME' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.01  Med: 0.73 Max: 0.99
Current: 0.42
-0.01
0.99
Debt-to-Equity 0.99
NAS:CRME's Debt-to-Equity is ranked lower than
77% of the 461 Companies
in the Global Biotechnology industry.

( Industry Median: 0.27 vs. NAS:CRME: 0.99 )
Ranked among companies with meaningful Debt-to-Equity only.
NAS:CRME' s Debt-to-Equity Range Over the Past 10 Years
Min: -162.34  Med: 0.03 Max: 4.14
Current: 0.99
-162.34
4.14
Piotroski F-Score: 4
Altman Z-Score: -6.68
Beneish M-Score: -2.89
WACC vs ROIC
-7.91%
-79.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -89.64
NAS:CRME's Operating Margin % is ranked higher than
51% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. NAS:CRME: -89.64 )
Ranked among companies with meaningful Operating Margin % only.
NAS:CRME' s Operating Margin % Range Over the Past 10 Years
Min: -4312.67  Med: -237.87 Max: 55.51
Current: -89.64
-4312.67
55.51
Net Margin % -110.82
NAS:CRME's Net Margin % is ranked lower than
53% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. NAS:CRME: -110.82 )
Ranked among companies with meaningful Net Margin % only.
NAS:CRME' s Net Margin % Range Over the Past 10 Years
Min: -3763.2  Med: -97.34 Max: 105.81
Current: -110.82
-3763.2
105.81
ROE % -89.72
NAS:CRME's ROE % is ranked lower than
75% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. NAS:CRME: -89.72 )
Ranked among companies with meaningful ROE % only.
NAS:CRME' s ROE % Range Over the Past 10 Years
Min: -142.44  Med: -83 Max: 116.12
Current: -89.72
-142.44
116.12
ROA % -39.68
NAS:CRME's ROA % is ranked lower than
59% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. NAS:CRME: -39.68 )
Ranked among companies with meaningful ROA % only.
NAS:CRME' s ROA % Range Over the Past 10 Years
Min: -101.59  Med: -37.63 Max: 51.35
Current: -39.68
-101.59
51.35
ROC (Joel Greenblatt) % -463.05
NAS:CRME's ROC (Joel Greenblatt) % is ranked lower than
52% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. NAS:CRME: -463.05 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:CRME' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1657.72  Med: -728.23 Max: 1550.15
Current: -463.05
-1657.72
1550.15
3-Year Revenue Growth Rate 53.10
NAS:CRME's 3-Year Revenue Growth Rate is ranked higher than
87% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. NAS:CRME: 53.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:CRME' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 34.3 Max: 227.7
Current: 53.1
0
227.7
GuruFocus has detected 3 Warning Signs with Cardiome Pharma Corp $NAS:CRME.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:CRME's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

CRME Guru Trades in Q3 2016

Jim Simons 162,613 sh (+80.25%)
» More
Q4 2016

CRME Guru Trades in Q4 2016

Jim Simons 215,013 sh (+32.22%)
» More
Q1 2017

CRME Guru Trades in Q1 2017

Jim Simons 253,413 sh (+17.86%)
» More
Q2 2017

CRME Guru Trades in Q2 2017

Jim Simons 350,713 sh (+38.40%)
» More
» Details

Insider Trades

Latest Guru Trades with CRME

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 3741
Compare:TSXV:ABCN, XCNQ:CRZ, NAS:SRRA, TSX:HBP, TSX:NEPT, TSX:CXR, TSXV:EMH, TSX:ONC, TSXV:TBP, TSXV:EMC, NAS:XENE, TSXV:COV, TSX:TRIL, TSXV:MPH, XCNQ:THC, OTCPK:IGXT, TSXV:BTI, TSX:APS, TSXV:CZO, XCNQ:VGW » details
Traded in other countries:COM.Canada, CKO1.Germany,
Headquarter Location:Canada
Cardiome Pharma Corp is a specialty pharmaceutical company. It is engaged in the development and commercialization of cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.

Cardiome Pharma is a Canadian company that develops drugs to treat cardiovascular diseases. The firm's lead drug, vernakalant, aims to treat atrial fibrilation, or the irregular beating of the upper chambers of the heart. The firm is developing the drug in both oral and intravenous formulations. The IV form is currently marketed in parts of the world as Brinavess. Merck had been developing the oral form, but has discontinued work on the drug.

Ratios

vs
industry
vs
history
PB Ratio 2.37
CRME's PB Ratio is ranked lower than
55% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CRME: 2.37 )
Ranked among companies with meaningful PB Ratio only.
CRME' s PB Ratio Range Over the Past 10 Years
Min: 1.02  Med: 6.27 Max: 33.74
Current: 2.37
1.02
33.74
PS Ratio 2.74
CRME's PS Ratio is ranked higher than
72% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. CRME: 2.74 )
Ranked among companies with meaningful PS Ratio only.
CRME' s PS Ratio Range Over the Past 10 Years
Min: 2.44  Med: 10.97 Max: 303.15
Current: 2.74
2.44
303.15
EV-to-EBIT -3.05
CRME's EV-to-EBIT is ranked lower than
99.99% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. CRME: -3.05 )
Ranked among companies with meaningful EV-to-EBIT only.
CRME' s EV-to-EBIT Range Over the Past 10 Years
Min: -153.4  Med: -4.8 Max: 799.5
Current: -3.05
-153.4
799.5
EV-to-EBITDA -3.57
CRME's EV-to-EBITDA is ranked lower than
99.99% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. CRME: -3.57 )
Ranked among companies with meaningful EV-to-EBITDA only.
CRME' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.8  Med: -5 Max: 535
Current: -3.57
-19.8
535
EV-to-Revenue 2.88
CRME's EV-to-Revenue is ranked higher than
67% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: 13.06 vs. CRME: 2.88 )
Ranked among companies with meaningful EV-to-Revenue only.
CRME' s EV-to-Revenue Range Over the Past 10 Years
Min: -13.7  Med: 7.9 Max: 295.2
Current: 2.88
-13.7
295.2
Current Ratio 4.81
CRME's Current Ratio is ranked lower than
54% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. CRME: 4.81 )
Ranked among companies with meaningful Current Ratio only.
CRME' s Current Ratio Range Over the Past 10 Years
Min: 1.14  Med: 6.58 Max: 97.75
Current: 4.81
1.14
97.75
Quick Ratio 4.12
CRME's Quick Ratio is ranked lower than
57% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. CRME: 4.12 )
Ranked among companies with meaningful Quick Ratio only.
CRME' s Quick Ratio Range Over the Past 10 Years
Min: 1.07  Med: 6.35 Max: 97.75
Current: 4.12
1.07
97.75
Days Inventory 284.12
CRME's Days Inventory is ranked lower than
83% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. CRME: 284.12 )
Ranked among companies with meaningful Days Inventory only.
CRME' s Days Inventory Range Over the Past 10 Years
Min: 207.89  Med: 255.33 Max: 1286.27
Current: 284.12
207.89
1286.27
Days Sales Outstanding 84.93
CRME's Days Sales Outstanding is ranked lower than
63% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. CRME: 84.93 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRME' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.04  Med: 127.18 Max: 540.02
Current: 84.93
4.04
540.02
Days Payable 165.64
CRME's Days Payable is ranked higher than
83% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. CRME: 165.64 )
Ranked among companies with meaningful Days Payable only.
CRME' s Days Payable Range Over the Past 10 Years
Min: 165.64  Med: 213.12 Max: 2230.17
Current: 165.64
165.64
2230.17

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.70
CRME's 3-Year Average Share Buyback Ratio is ranked lower than
76% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CRME: -28.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRME' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -58  Med: -16.75 Max: 1.4
Current: -28.7
-58
1.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 18.08
CRME's Price-to-Net-Current-Asset-Value is ranked lower than
92% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. CRME: 18.08 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRME' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.11  Med: 7.94 Max: 279.5
Current: 18.08
1.11
279.5
Price-to-Tangible-Book 14.47
CRME's Price-to-Tangible-Book is ranked lower than
95% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CRME: 14.47 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRME' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.11  Med: 7.43 Max: 232.17
Current: 14.47
1.11
232.17
Price-to-Median-PS-Value 0.25
CRME's Price-to-Median-PS-Value is ranked higher than
87% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. CRME: 0.25 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRME' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 2.87 Max: 138.46
Current: 0.25
0.23
138.46
Earnings Yield (Greenblatt) % -32.98
CRME's Earnings Yield (Greenblatt) % is ranked lower than
65% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. CRME: -32.98 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRME' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -4444.2  Med: -12.65 Max: 85271.5
Current: -32.98
-4444.2
85271.5

More Statistics

Revenue (TTM) (Mil) $23.21
EPS (TTM) $ -0.82
Beta-0.46
Short Percentage of Float1.26%
52-Week Range $2.09 - 4.84
Shares Outstanding (Mil)33.80

Analyst Estimate

Dec17 Dec18 Dec19 Dec20
Revenue (Mil $) 29 46 71 102
EPS ($) -0.64 -0.33 0.04 0.50
EPS without NRI ($) -0.64 -0.33 0.04 0.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:CRME

Headlines

Articles On GuruFocus.com
Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Sep 12 2017 
Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Sep 05 2017 
New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of BR Aug 30 2017 
Cardiome Provides U.S. Regulatory Update For BRINAVESS Aug 21 2017 
Cardiome To Hold Second Quarter 2017 Financial Results Conference Call On August 8 Aug 01 2017 
Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen Jul 17 2017 
Cardiome Pharma Corp. Announces Voting Results Jun 23 2017 
Cardiome Announces Licensing Agreement for XYDALBA™ (Dalbavancin Hydrochloride) to Support Planned Jun 21 2017 
Cardiome Announces Commercial Launch of BRINAVESS® (Vernakalant Hydrochloride) in Canada Jun 12 2017 
Cardiome Reports Changes To Senior Management Team May 16 2017 

More From Other Websites
Cardiome Pharma Corp. :CRME-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017 Sep 13 2017
Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in... Sep 12 2017
Cardiome, Pipeline Offers Opportunities Beyond Brinavess Sep 06 2017
Cardiome to Present at the Rodman & Renshaw 19th Annual Global Investment Conference Sep 05 2017
New Data Presented at European Society of Cardiology Congress 2017 Highlights Clinical Benefit of... Aug 30 2017
What Falling Estimates & Price Mean for Cardiome (CRME) Aug 25 2017
Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug Aug 25 2017
Cardiome Provides U.S. Regulatory Update For BRINAVESS Aug 21 2017
Cardiome reports 2Q loss Aug 08 2017
Cardiome Reports Second Quarter 2017 Financial Results Aug 08 2017
Investor Network: Cardiome Pharma Corp. to Host Earnings Call Aug 08 2017
Cardiome To Hold Second Quarter 2017 Financial Results Conference Call On August 8 Aug 01 2017
Cardiome Announces Health Canada Approval of AGGRASTAT® High Dose Bolus Regimen Jul 17 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}